NCT06065462View on ClinicalTrials.gov

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Ovarian Clear Cell Carcinoma
Interventions
DRUG

Dostarlimab

Given by vein (IV)

DRUG

LB-100

GIven by vein (IV)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (2)

GSK Pharma
Lixte
All Listed Sponsors
collaborator

GSK Pharma

UNKNOWN

collaborator

Lixte

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER